Literature DB >> 35550617

A de novo variant in CASK gene causing intellectual disability and brain hypoplasia: a case report and literature review.

Ying Zhang1,2, Yanyan Nie1, Yu Mu1, Jie Zheng2, Xiaowei Xu3,4, Fang Zhang1, Jianbo Shu5,6, Yang Liu7.   

Abstract

BACKGROUND: The pathogenic variation of CASK gene can cause CASK related mental disorders. The main clinical manifestations are microcephaly with pontine and cerebellar hypoplasia, X-linked mental disorders with or without nystagmus and FG syndrome. The main pathogenic mechanism is the loss of function of related protein caused by variant. We reported a Chinese male newborn with a de novo variant in CASK gene. CASE
PRESENTATION: We present an 18-day-old baby with growth retardation and brain hypoplasia. Whole-exome sequencing was performed, which detected a hemizygous missense variant c.764G > A of CASK gene. The variant changed the 255th amino acid from Arg to His. Software based bioinformatics analyses were conducted to infer its functional effect.
CONCLUSIONS: In this paper, a de novo variant of CASK gene was reported. Moreover, a detailed description of all the cases described in the literature is reported. CASK variants cause a variety of clinical phenotypes. Its diagnosis is difficult due to the lack of typical clinical symptoms. Genetic testing should be performed as early as possible if this disease is suspected. This case provides an important reference for the diagnosis and treatment of future cases.
© 2022. The Author(s).

Entities:  

Keywords:  Brain dysplasia; CASK gene; Gene variant; Intellectual disability; Microcephaly

Mesh:

Substances:

Year:  2022        PMID: 35550617      PMCID: PMC9097383          DOI: 10.1186/s13052-022-01248-z

Source DB:  PubMed          Journal:  Ital J Pediatr        ISSN: 1720-8424            Impact factor:   3.288


Background

CASK gene located in Xp11.4 [1] and is an important gene in mammals, which plays a very important role in metabolic regulation and affects the development of postnatal brain [2]. CASK gene variants cause a wide range of human phenotypes. The pathogenic variants can lead to CASK related mental disorders. It is reported that CASK gene variant can mainly lead to these phenotypes: severe intellectual disability, microcephaly with pontine and cerebellar hypoplasia (MICPCH, OMIM: 300,749) in women. In men, mild to severe X-related mental disorders were observed with or without nystagmus, microcephaly and other malformations, and FG syndrome. The varied clinical phenotypes depend on the types of variants [3-5]. CASK gene encodes calcium/ calmodulin dependent serine protein kinase, which belongs to the membrane associated guanosine kinase (MAGUK) scaffold protein family. MAGUK protein plays an important role in the ionic channel targeting, anchoring and signal transduction of synapses, as well as regulating neural activity. CASK is a special member of p55 subfamily and is the only MAGUK which contains the calcium/ calmodulin dependent kinase (CaMK) domain at its N-terminal. CASK protein contains five domains, including two L27 (Lin2, lin7) domains, one PDZ domain and one integrated SH3 and GUK domain [6]. The CASK disorder is rare. ZHANG Yi et al. [7] reported a case of Chinese children in 2019 which is the first one in China. Here, we reported the second case and identified a de novo variant c.764G > A (p. Arg255His) of CASK gene in China. Bioinformatics software were used to predict the effects of the missense variant on the function of the CASK protein. Additionally, we reviewed the previously reported cases of CASK gene variants from different ethnic groups (Table 1), which contained the nucleotide changes, amino acid changes and clinical phenotypes caused by gene variants [8-23].
Table 1

Summary table of reported CASK variants

PublicationNoSexAgePOPLOCVariantAACTOVGenoPhenotype
Juliane Najm et.al. (2008) [21]1F-------MICPCH, ID, deafness
2F-------MICPCH, ID
3F-------MICPCH, ID
4F--Ex21c.1915C > Tp.(R639*)NonHeteMICPCH, ID
5M--Ex9c.915G > Ap. = Spl-MICPCH, ID
Shin Hayashi, et al. (2008) [24]6F5y--arrXp11.4p11.3 (41,500,243–45,480,187) × 1---MICPCH, DD, strabismus, nystagmus
Giulio Piluso et al. (2009) [3]7M-ItaEx2c.83G > Tp. (R28L)MisHemiFG, ID, hypotonia
Patrick S Tarpey et al. (2009) [25]8M---c.829C > Tp.(Y268H)Mis-ID
9---Ex22c.2129A > Gp.(D710G)Mis-ID, nystagmus
10----c.2767C > Tp.(W914R)Mis-ID, nystagmus
11----c.1188C > Tp.(P396S)Mis-ID
Anna Hackett et al. (2010) [4]12M--Ex22c.2129A > Gp.(D710G)Mis-ID, nystagmus, strabismus
13M--Ex27c.2756 T > Cp.(W919R)Mis-ID, nystagmus, epilepsy
14M--Ex8c.802 T > Cp. (Y268H)Mis-ID, epilepsy
15M-A-AEx13c.1186C > Tp.(P396S)Mis-ID, unsteady gait, resting tremor
16M--Ex23c.2183A > Gp.(Y728C)Mis-ID, cerebellar hypoplasia
17M--Ex26c.2521-2A > Tp.(841_868 and p.841_843 del ALK)Mis-ID, nystagmus
Ute Moog et al. (2011) [22]18F10 mFreIn2c.173-2A > C-Frs-ID, small nose, micrognathia,
19F10 mFreEx3c.174 T > Ap.(D58E)--ID, small nose, micrognathia,
20F5yBriIn8c.831 + 2 T > G-Frs-ID, epilepsy, BCH
21F

2y

10 m

FreIn17c.1668 + 1G > A-Spl-BCH, hypotonia, small nose
22F4yAmeEx5c.379C > Tp.(E127*)--Axial hypotonia, peripheral hypertonia,
23F8yAmeEx17c.1639C > Tp.(Q547*)--BCH, hypertonia, strabismus
24F2y4mAmeIn5c.430–2 A > T-Spl-BCH, hypertonia, dyskinesia
Jun-ichi Takanashi et al. (2012) [26]25F7yJap-c.173_173 + 1delGG---MICPCH, DD
26F11yJap-c.2302 + 1 del T---MICPCH, DD
27F8yJap-c.1910G > Ap.(G637D)--MICPCH, DD
28M2yJap-c.1061 T > Cp.(L348P)--MICPCH, DD, epilepsy
29F24yJapEx4c.316C > Gp. (R106 *)--MICPCH, DD, epilepsy
Lydie Burglen et al. (2012) [27]30F7y-Ex1-8Xp11.4 deletion 0.3 Mb---PCH, ID, DD, FD, spasticity
31F3y-Ex 1–27Xp11.3-p11.4 deletion 3 Mb---ID, DD, deafness, FD, spasticity
32F14y-Ex1Xp11.4 deletion 0.5 Mb---ID, DD, FD spasticity
33F13y-Ex21c.1968G > Ap.(W656*)Non-ID, DD, FD, epilepsy
34F3y-In21c.2040–2 A > G-Spl-ID, DD, deafness spasticity
35F1y-Ex22c.2080C > Tp.(Q694*)Non-ID, DD, FD
36F1y-Ex22c.2074C > Tp.(Q692*)Non-ID, DD, epilepsy
37F10y-In24c.2302 + 5G > A-Spl-ID, DD, deafness, epilepsy,
38F14y-In21c.2039 + 1G > T-Spl-ID, DD, FD, spasticity,
39F8y-Ex21c.1970G > Ap.(W657*)Non-ID, DD, FD, stereotypies
40F3y 6 m-Ex15c.1501dupAp.(M501fs)Frs-

ID, DD, FD,

stereotypies

41M15y-Ex4c.[= /316C > T]p.(R106*)mosNon-ID, DD, FD, stereotypies
42M13y-In3c.278 + 1G > A-Spl-ID, DD, FD, epilepsy
Vassili Valayannopoulos,et al. (2012) [2843F13y--c.1970G > Ap.(W657*)--MICPCH, trunk ataxia, swallowing difficulties
44F8y-Ex16c.1577delGp.(R526Sfs-X74)Frs-MICPCH, trunk ataxia, dystonia, spasticity
4513y-Ex21c.1968G > Ap.(W656*)--MICPCH, dystonia, swallowing difficulties
Hirotomo Saitsu, et al. (2012) [29]46M4y-Ex2(NG_016754.1: g.17883_129055deldeletion 111 Mb--MICPCH, OS, micropenis
47M4y-Ex1c.1A > Gp.(M1V)-HemiMICPCH, OS,
Shin Hayashi et al. (2012) [5]48F2y 8 mJapEx2c.79C > Tp.(R27*)Non-ID, DD, deafness, microcephaly, hypotonia
49F2yJap-c.316C > Tp.(R106*)Non-ID., deafness, microcephaly, hypotonia
50F2y 8 mJapEx27c.2632C > Tp.(Q878*)Non-ID, hyperopia microcephaly
51F11 mJapEx3c.243_244delTAp.(Y81*)Frs-microcephaly, ID
52F

7y

9 m

JapIn4c.357-1G > Ap.S119Rfs7X, p.H120Rfs22XSpl-microcephaly, ID
53F14yJap-c.2041-1G > C

p.W608Cfs29X,

p.W608Cfs3X

Spl-Microcephaly, ID
54F1y 9 mJap-arrXp11.4p11.3 (41,009,876–44,100,501) × 1---MICPCH, DD, deafness, hypotonia
55F2yJap-arrXp11.4p11.3 (41,337,795–42,468,013) × 1---MICPCH, DD
56F12yJap-arrXp11.4 (41,405,593–41,570,391) × 3---MICPCH, DD, epilepsy, strabismus
57F2 mJap-arrXp11.4 (41,382,179–41,540,922) × 3 arrXp11.22 (56,012,908–56,275,153) × 3---MICPCH, DD, epilepsy, hypotonia, strabismus
Nakamura K. et al. (2014) [23]58M--Ex3c.227_228delp.(E76Vfs*6)FrsHemiPCH, TOF, epilepsy
JacquesL. Michaud et al. (2014) [30]59F36 m-Ex2c.82C > Tp.(R28*)--ID, cortical and cerebellar atrophy
Ute Moog et al. (2015) [31]60M7 m-Ex7c.704_708delp.(K236Efs* 10ex7dn)Frs-MICPCH, ID, DD, epilepsy, hypotonia
61M10 m--dup ex10 – 16dn---MICPCH, ID, DD, epilepsy, hypotonia
62M5y--c.1A > G ex1dn---MICPCH, ID, DD, epilepsy, hypotonia
63M15 m--c.79C > Tp.(R27*ex2 dn)--MICPCH, ID, DD, epilepsy, hypotonia
64M7 m--dup ex4–20 mos---MICPCH, ID, DD, epilepsy, hypertonia
65M16 m--del ex1mos---MICPCH, ID, DD, hypertonia
66M29 m--del ex3–9 mos---MICPCH, ID, DD
67M20 m--dup ex1–5 mat---Microcephaly, DD
Tomoshi Nakajiri et al. (2015) [32]68F13yJapEx21c.1896dupCp.(C633Lfs*2)FrsHeteMICPCH, epilepsy
Patrick Rump et al. (2016) [33]69F22y--c.2302 + 2 T > G--HeteMICPCH, ID, DD, FD, epilepsy
Lucía Rivas et al. (2017) [34]70F5y--deletion254.01 Kb---MICPCH, WS
Shin Hayashi et al. (2017) [35]71F1y--c.868G > Tp.(E290*)--MICPCH, DD
72F5 m--c.761-762delCTp.(S246*)--MICPCH, hypotonia
73F15y--c.1006-1012del ACCTCCTp.(T336Qfs* 23)--MICPCH, epilepsy, DD, hypotonia
74F4y2m--c.2103delTp.(F710Lfs* 26)--MICPCH, DD
75F1y--c.1677dupGp.(R560Afs* 20)--MICPCH, DD
76F17y--c.2508delTp.(L837*)--MICPCH, DD, epilepsy
77F11y--c.1896dupCp.(C633Lfs*2)--MICPCH, epilepsy DD, hypertonia
78F1y--c.1582 + G > A---MICPCH, DD
79F3y--c.2302 + 1G > T---MICPCH
80M4y 4 m--c.317G > Cp.(R106P)--MICPCH
81M2y--c.[= /1493_1503 + 10delATGAACCAATGGTAAGTAGGAinsGG]p.(D498Gfs* 12)--MICPCH, epilepsy DD, hypotonia
82F6y4m--arrXp11.4p11.3 (41,618,898–43,755,475) × 1---MICPCH, DD, epilepsy
83F4y--arrXp11.4p11.3 (41,145,925–46,090,321) × 1---MICPCH,
84F12y8m--arrXp11.4p11.3 (41,163,139–44,592,980) × 1---MICPCH, DD, glaucoma, PHPV
85F---arrXp11.4 (41,442,660–41,527,850) × 3---Died
Bernt Popp et al. (2017) [36]86F5yGerEx2c.68delp.(F23Sfs*18)Frs-MICPCH, deafness, ID hypertonia
Stephanie C. DeLuca et al. (2017) [37]87F54 m--c.2221 + 1G > C---MICPCH, single- word speech
88F89 m-Ex17c.1609C > Tp.(R537*)--MICPCH
89F24 m--c.106C > Tp.(Q36*)--MICPCH, DD
P. Dunn, et al. (2017) [38]90M6y 6 m-Ex26c.2521–2 A > G---FG, nystagmus
Toshiyuki Seto et al. (2017) [39]91M5y-Ex15c.1424G > Tp.(S475I)Mis-microcephaly, ASD
92F3y--c.1424G > Tp.(S475I)Mis-DD, ASD
Babylakshmi Muthusamy et al. (2017) [40]93M14y & 17yInd-E550_dupStop gain and in-frame insertion-Hemimicrocephaly, clinodactyly
Xiuhua Bozarth et al. (2018) [41]94F-ME-C-c.2179–2181del GTAp.(V727del)-Heteinfantile spasms, nystagmus, strabismus
Leslie E. W. LaConte et al.(2018) [42]95F12y--c.1556 T > Cp.(M519T),Mis-MICPCH, gait ataxia, nystagmus
96F5y--c.1989G > A:p.(G659D)MisHeteMICPCH strabismus
97F9y--c.626 T > Cp.(L209P)--MICPCH, ID, motor disability
Hiroaki Murakami et al. (2019) [43]98F5y--c.2041C > Tp.(R681*)Non-microcephaly, BCH, DD, hypotonia
Francesca Cristofoli et al. (2019) [44]99F25yEur-c.1315–7 A > Gp.(M438-A 439 insH*)Spl-ID, DD, dystonia, small cerebellum
100F21yEur-c.C109Tp.(Q37*)Non-ID, DD, visual impairment
101F6yEur-c.T626Cp.(L209P)Nonsy-nonym-ous-ID, DD, FD, hypotonia, nystagmus
102F17yEur-c.2302 + 1 G > Ap.(G741-H768 delinsD)Spl-ID, DD, Visual impairment
ZHANG Yi, et al. (2019) [7]103M3 m 27dChiEx20c.1818_1821dup AACTp.(T608Nfs* 16)FrsHemiMICPCH, DD, FD, hypertonia
This study104M18dChiEx8c.764G > Ap.(R255H)MisHemimicrocephaly, ID, DD, epilepsy, deafness

Abbreviations: POP Population, LOC Location, AAC Amino acid change, TOV Type of variant, Geno Genotype, F Female, M Male, Ita Italian, A-A African-American, Fre French, Bri British, Ame American, Jap Japanese, Ger German, Ind Indian, MEC Mixed-European Caucasian, Eur European, Chi Chinese, Ex Exon, In Intron, Non Nonsense, Spl Splicing, Mis Missense, Frs Frameshift, Hete Heterozygous, Hemi Hemizygote, MICPCH Microcephaly with pontine and cerebellar hypoplasia, ID Intellectual disability, DD Developmental delay, FG FG syndrome, BCH Brain stem and cerebellar hypoplasia, PCH Pontine and cerebellar hypoplasia, FD Feeding difficulties, OS Ohtahara syndrome, TOF Tetralogy of Fallot, WS West syndrome, PHPV Persistent hyperplasia of primary vitreous, ASD Autism spectrum disorder

Summary table of reported CASK variants 2y 10 m ID, DD, FD, stereotypies 7y 9 m p.W608Cfs29X, p.W608Cfs3X Abbreviations: POP Population, LOC Location, AAC Amino acid change, TOV Type of variant, Geno Genotype, F Female, M Male, Ita Italian, A-A African-American, Fre French, Bri British, Ame American, Jap Japanese, Ger German, Ind Indian, MEC Mixed-European Caucasian, Eur European, Chi Chinese, Ex Exon, In Intron, Non Nonsense, Spl Splicing, Mis Missense, Frs Frameshift, Hete Heterozygous, Hemi Hemizygote, MICPCH Microcephaly with pontine and cerebellar hypoplasia, ID Intellectual disability, DD Developmental delay, FG FG syndrome, BCH Brain stem and cerebellar hypoplasia, PCH Pontine and cerebellar hypoplasia, FD Feeding difficulties, OS Ohtahara syndrome, TOF Tetralogy of Fallot, WS West syndrome, PHPV Persistent hyperplasia of primary vitreous, ASD Autism spectrum disorder

Case presentation

The patient was an 18-day-old male baby, gravida 3, para 1, born in full term with a birth weight of 2790 g. The condition of intrauterine distress was unknown, and the history of asphyxia was denied. Crying after birth but slightly weak. Apgar score was unknown. The couple denied the family genetic disease history. The patient was hospitalized in Tianjin Children's hospital mainly due to sucking weakness. When he was fed for the first time after birth, he was not willing to take the initiative to suck. He was fed with a spoon and could swallow. The infant rarely cries and cry weakly, with no fever and hoarseness, moaning and other symptoms. Admission examination: weight 2840 g, length 50 cm, head circumference 33 cm. The child's consciousness was weak and he occasionally had inspiratory laryngitis, hypotonia of the extremities. Holding reflex and embracing reflex were normal, the foraging reflex ( ±), sucking reflex ( ±). When he was crying, the corners of his mouth inclined to the left. His left nasolabial groove became slightly shallow along with right hand slightly hanging wrist, right foot slightly turned inward, and his right-hand pass-through palm. Laryngoscope showed that the arytenoid epiglottic folds on both sides were close to each other, and the mucosa was slightly tense. The cricoarytenoid joint were adducted, and the throat entrance was slightly blocked. Head Magnetic Resonance Imaging(MRI)showed that the bilateral frontal parietal lobes had slightly intense T1 and T2 signal shadows. The extracerebral space was widened, and the posterior angles of bilateral lateral ventricles were widened. Brainstem auditory evoked potential test showed deafness in the left ear and abnormality in the right brainstem. Ambulatory electroencephalogram examination and cerebrospinal fluid test were normal. Neuroelectrophysiological examination showed that there was no abnormality in facial nerve detection. After admission, the patient was given anti-infective treatment of Latamoxef disodium, expectorant therapy of ambroxol and other symptomatic treatment. Six days after hospitalization, there was no fever in the child and the supplementary feeding became better. The family members required to be discharged from the hospital. Telephone follow-up at the age of 4–5 months, the symptoms of sucking weakness were slightly better than before. Later, spasm occurred at the age of 6 months and he was diagnosed epilepsy which was characterized by cyanosis of lips and clenching of both hands. After 9 months of oral medication with Sodium Valproate and Topiramate, there was no obvious improvement in condition. At present, the child was 14 months old, with a weight of 6000 g. He has microcephaly compared with children of the same age (family members did not measure the head circumference), accompanied by severe developmental delay and intellectual disability. He still can’t raise head, speak and walk. The results of Whole-exome sequencing (WES) showed that there was a hemizygous missense variant c.764G > A in exon 8 of CASK gene in proband. The variant changed the 255th amino acid from Arg to His. Because of the gene is located on the X chromosome, the paternal sample of the child does not need to be detected. Sanger sequencing of the child showed that the variant was not detected in his mother (Fig. 1). The pathogenicity classification of variants by American College of Medical Genetics (ACMG) guidelines [41] indicated that c.764G > A (p. Arg255His) is of pathogenic. The variant was not included in HGMD, 1000 Genomes, gnomAD and ESP6500 public databases.
Fig. 1

Sanger sequencing of a family with CASK gene c.764G > A missense variant

Sanger sequencing of a family with CASK gene c.764G > A missense variant Prediction of functional effects of CASK variant showed the c.764G > A variant was possibly damaging (Fig. 2). Amino acid sequence alignment showed that the variant occurred at a highly conserved residue in CASK with surrounding amino acid residues being conserved between orthologs (Fig. 3). Protein structure 3D modeling was performed. It was shown that the variant (p. Arg255His) had a damaging effect on the CASK protein structure stability (Fig. 4).
Fig. 2

Conservation analysis of CASK protein sequences across different species. Amino acid positions of variants are highlighted in red box

Fig. 3

Prediction of functional effects of CASK variant

Fig. 4

Three-dimensional structure model of CASK protein. Native(Arg, A)and mutant (His, B) side-chains at position 255 are shown in blue. The H-bonds are shown in dotted green line

Conservation analysis of CASK protein sequences across different species. Amino acid positions of variants are highlighted in red box Prediction of functional effects of CASK variant Three-dimensional structure model of CASK protein. Native(Arg, A)and mutant (His, B) side-chains at position 255 are shown in blue. The H-bonds are shown in dotted green line

Discussion and conclusions

CASK is widely distributed in different brain regions of mice. The insertion variant and targeted knockout of CASK gene cause the death of mice within 1–2 days after birth. The mice exhibit a cleft palate and apoptosis of thalamic cell increased. The research results indicate the important role of CASK gene in the nervous system [35]. In human fetal tissues, CASK is most expressed in brain, followed by kidney and lung, and the expression level of CASK in brain is 3–5 times higher than other organs [42].Although CASK is expressed in neurons, it is not limited to neurons. Studies have shown that CASK is widely present in basement membrane, lateral membrane or lateral basement membrane in different epithelial cells [45]. The structure of CASK suggests that CASK plays an important role in signal transduction, intercellular connection, cytoskeleton and binding to membrane proteins [33].CASK interacts with a variety of cell proteins and plays different roles according to the time and location of expression [37]. Firstly, it is involved in the formation of synapses and the interaction between synapses [46]. For example, CASK regulates axon growth and branch by interacting with Bcl11A [24]; Interaction between CASK and syndecan-2 regulates maturation of dendritic protein [25]. At presynaptic sites, CASK forms compound with MALS/Mint-1/Liprinα through its CaMK and L27A domains. This compound is involved in the organization of synaptic vesicles and regulates the release of neurotransmitters [26]. Secondly, CASK involves protein transport of NMDA glutamate receptor and synaptic target of N-type calcium channel. Through its PDZ and SH3 domains, CASK forms targeted interaction and regulation with neurexin-1 and ion channel synapses in a CDK5-dependent manner. Thirdly, CASK regulating gene expression and neurodevelopment. CASK can enter the nucleus and bind to a specific DNA sequence in the Tbr-1 complex. As a co-activator of Tbr-1, CASK induces the transcription of this sequence, so as to regulate the expression of genes related to the development of cerebral cortex, such as RELN [37]. Protein kinase A phosphorylation regulates the interaction between CASK and Tbr-1 and it is an important regulatory factor of CASK in the nucleus [27]. Y-P30 can control the nuclear localization of CASK in a cell adhesion molecule dependent manner [28]. CASK is involved in many cellular pathways, including mitochondrial, synaptic and protein metabolism. The dysfunction of these cells may be the basis of complex neurological diseases related to CASK dysfunction [29]. In 2008, Najm J et al. first reported the heterozygous deletion and variant of CASK gene in girls and boys with severe pontine and cerebellar hypoplasia [30]. Since then, 104 pathogenic variants of CASK gene have been identified through next generation sequence (Table 1). According to these publications, CASK variants cause a variety of clinical phenotypes. These cases shown that CASK gene does not have a hot variant site that causes pathogenic clinical phenotype. Inactivated variant is more common in female patients, and the clinical phenotype is more serious. MICPCH is a rare X-linked disease, usually seen in women, characterized by neurodevelopmental delay, microcephaly, and pontocerebellar hypoplasia. The main clinical phenotypes of the disease are severe developmental delay or intellectual disability, microcephaly after birth, often accompanied by slow growth, language development disorders, axial muscle tone reduction with or without increased limb muscle tone, optic nerve hypoplasia and / or other eye abnormalities, such as nystagmus. Patients often have special facial phenotypes including microcephaly, protruding broad bridge and tip of nose, small nose or short nose, small jaw deformity, big ears, with varying degrees of pons and cerebellum hypoplasia and progressive aggravation, as well as hearing loss, epilepsy etc. [31, 32]. There are also some female patients without microcephaly and pontine dysplasia. Bozarth X et al. reported a case of early-onset infantile spasm caused by CASK frame deletion variant in a girl. Brain MRI showed focal supratentorial brain malformation. EEG showed peak rhythm disorder, but no MICPCH [34]. The relationship between genotype and phenotype of CASK variant is not clear. CASK inactivating variants appear to account for the majority of MICPCH cases and with severer phenotypes [36]. It is fatal to men in the prenatal or neonatal period. Najm J et al. reported a male child died at 2 weeks after birth. In addition to deletion or duplication variant, women with MICPCH phenotype also have heterozygous deletion variants, including nonsense, frameshift and splice site variants [30]. In general, CASK missense variant is common in boys with X-linked intellectual disability. The clinical phenotype is not very serious, and it is usually asymptomatic in girls. However, Laconte L E W et al. reported three women with CASK missense variant in heterozygote, and they have severe intellectual disability, microcephaly and hindbrain hypoplasia [38]. The child in our case was born with weakness sucking, decreased muscle tension of limbs, abnormal face, right hand and right foot deformity, deafness of left ear, epilepsy, microcephaly, serious developmental delay and mental disorder. The results of next generation sequencing showed that there was a hemizygote missense variant c.764gG > A, p. (Arg255His) in exon 8 of CASK gene in children. According to the classification of gene variation by ACMG, the variant could be classified as pathogenic. The patient was a male child with pathogenic missense variant. Compared with literature reports published, the missense variant is a de novo variant, and the clinical phenotype of the patient is consistent with the published cases. MRI of CASK variant patients showed that the size of the corpus callosum was normal, the proportion of brain/ corpus callosum was low, and the area of brain, pons, midbrain, cerebellar vermis and hemispheres were reduced. Some studies have shown that MRI results of hypoplasia and normal or large corpus callosum in the middle and posterior brain of girls with microcephaly and neurodevelopmental delay should indicate the possibility of CASK variant, especially in the case of low brain / corpus callosum ratio [39]. In terms of disease diagnosis, WES is a powerful tool for the diagnosis of highly heterogeneous neurodevelopmental disorders [40]. Children with microcephaly will face lifelong psychomotor, cognitive and communication disorders. For this kind of children, their motor development is often delayed for several years, and they are far behind the children of the same age in intelligence and communication ability. These children usually have serious speech disorders. DeLuca SC et al. conducted intensive treatment on three girls with CASK gene heterozygote variant and MICPCH. Conducting targeted trials to improve fine and coarse motor skills, visual motor coordination, social and communication skills. Studies have shown that MICPCH children respond to intensive therapy aimed at improving function or independence [43]. The therapy can improve the life track and affect the quality of life. CASK is highly conserved in structure. LaConte LE et al. used a high-throughput imaging method to measure the misfolding tendency of CASK mutants, and proved that a chemical chaperone may be helpful to save the misfolding of CASK caused by missense variants. It providing a possibility for the treatment of structural variants in the future [44]. In summary, we reported a de novo variant of CASK gene. Moreover, a detailed description of all the cases described in the literature is reported. All published cases suggest that the variant of CASK can cause a variety of clinical phenotypes. Its diagnosis is difficult due to the lack of typical clinical symptoms. Genetic testing should be performed as early as possible if this disease is suspected. We believe that this case provides an important reference for the diagnosis and treatment of future cases.
  45 in total

1.  Mapping and expression analysis of the human CASK gene.

Authors:  D Stevenson; H G Laverty; S Wenwieser; M Douglas; J B Wilson
Journal:  Mamm Genome       Date:  2000-10       Impact factor: 2.957

2.  A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain.

Authors:  S Butz; M Okamoto; T C Südhof
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

3.  The location of human CASK at Xp11.4 identifies this gene as a candidate for X-linked optic atrophy.

Authors:  S D Dimitratos; D G Stathakis; C A Nelson; D F Woods; P J Bryant
Journal:  Genomics       Date:  1998-07-15       Impact factor: 5.736

4.  X-linked mental retardation gene CASK interacts with Bcl11A/CTIP1 and regulates axon branching and outgrowth.

Authors:  Ting-Yu Kuo; Chen-Jei Hong; Hsu-Ling Chien; Yi-Ping Hsueh
Journal:  J Neurosci Res       Date:  2010-08-15       Impact factor: 4.164

5.  Neuroradiologic features of CASK mutations.

Authors:  J Takanashi; H Arai; S Nabatame; S Hirai; S Hayashi; J Inazawa; N Okamoto; A J Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-01       Impact factor: 3.825

6.  The genetic landscape of infantile spasms.

Authors:  Jacques L Michaud; Mathieu Lachance; Fadi F Hamdan; Lionel Carmant; Anne Lortie; Paola Diadori; Philippe Major; Inge A Meijer; Emmanuelle Lemyre; Patrick Cossette; Heather C Mefford; Guy A Rouleau; Elsa Rossignol
Journal:  Hum Mol Genet       Date:  2014-04-29       Impact factor: 6.150

7.  A missense mutation in CASK causes FG syndrome in an Italian family.

Authors:  Giulio Piluso; Francesca D'Amico; Valentina Saccone; Ettore Bismuto; Ida Luisa Rotundo; Marina Di Domenico; Stefania Aurino; Charles E Schwartz; Giovanni Neri; Vincenzo Nigro
Journal:  Am J Hum Genet       Date:  2009-02-05       Impact factor: 11.025

8.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

9.  Comprehensive investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH).

Authors:  Shin Hayashi; Daniela Tiaki Uehara; Kousuke Tanimoto; Seiji Mizuno; Yasutsugu Chinen; Shinobu Fukumura; Jun-Ichi Takanashi; Hitoshi Osaka; Nobuhiko Okamoto; Johji Inazawa
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

Review 10.  The Involvement of Neuron-Specific Factors in Dendritic Spinogenesis: Molecular Regulation and Association with Neurological Disorders.

Authors:  Hsiao-Tang Hu; Pu-Yun Shih; Yu-Tzu Shih; Yi-Ping Hsueh
Journal:  Neural Plast       Date:  2015-12-24       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.